Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
Anifrolumab for Treatment of Refractory Cutaneous Lupus Erythematosus
Clin Exp Dermatol. 2022. Epub ahead of print doi:10.1111/ced.15335
First report of multiple cases of successful Cutaneous Lupus Erythematosus (CLE) treatment in active smokers with anifrolumab.
Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study
Rheumatology (Oxford). 2022;61(6):2413–2423 doi: 10.1093/rheumatology/keab685
Proof-of-concept study for the safety and efficacy of filgotinib (FIL) and lanraplenib (LANRA) in cutaneous lupus (CLE) fails to meet primary endpoint, but select subgroups displayed a numerically greater treatment response to FIL relative to placebo.
A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis
Kidney Int. 2022;101(2):403-413 doi: 10.1016/j.kint.2021.08.027
Post-hoc analysis data suggests that the addition of belimumab to standard therapy may be effective in preserving long-term kidney function in patients with lupus nephritis (LN).